Topics
Oligodendroglioma | Treatment | Chemotherapy
Home > Publications > Topics > Oligodendroglioma > Treatment > Chemotherapy
2024
Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C,
Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E,
Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier
L, Ramirez C, Younan N, Menei P, Dhermain F, Desenclos C,
Ghiringhelli F, Bourg V, Ricard D, Faillot T, Appay R, Tabouret E,
Nichelli L, Mathon B, Thomas A, Tran S, Bielle F, Alentorn A,
Iorgulescu JB, Boëlle PY, Labreche K, Hoang-Xuan K, Sanson M,
Idbaih A, Figarella-Branger D, Ducray F, Touat M; POLA Network.
Survival Outcomes Associated With
First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in
Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade
3 Oligodendroglioma.
J
Clin Oncol. 2024 Oct 2:JCO2400049. doi:
10.1200/JCO.24.00049. PMID:
39356975. Observational study˰
ˍ
*Rincon-Torroella J, Rakovec M, Kalluri AL, Jiang K, Weber-Levine
C, Parker M, Raj D, Materi J, Sepehri S, Ferres A, Schreck KC,
Aldecoa I, Lucas CG, Sair HI, Redmond KJ, Holdhoff M, Weingart J,
Brem H, Sánchez JJG, Ye X, Bettegowda C.
Impact
of upfront adjuvant chemoradiation on survival in patients with
molecularly defined oligodendroglioma: the benefits of PCV over
TMZ.
J
Neurooncol. 2024 Oct 9. doi:
10.1007/s11060-024-04829-6. PMID:
39382617. Observational study˰
ˍ
2025
Santos MDC, Rodrigues NMV, Gibram F, Gouhie FA, Campos ACP, de
Assis DV, Formentin C, Feher O, de Souza E Silva ARN, Hanna SA,
Chung C, Barbosa CC, Moraes FY, Maldaun MVC.
Adjuvant
chemoradiotherapy with procarbazine, lomustine, and vincristine
(PCV) or temozolomide for 1p/19q Co-deleted anaplastic
oligodendroglioma: a systematic review and network meta-analysis.
BMC
Cancer. 2025 Nov 18;25(1):1779. doi:
10.1186/s12885-025-15085-w. PMID:
41254593. Review; Meta-Analysis.
ˍ
Duran G, Pichardo-Rojas D, Ali AH, Passias P, Downes A, Ray WZ,
Zipfel GJ, Shakir HJ, Bauer A, Jea A, Dunn IF, Zuccato JA, Graffeo
CS, Janjua MB.
Comparing Isocitrate
Dehydrogenase Inhibitors with Procarbazine, Lomustine, and
Vincristine Chemotherapy for Oligodendrogliomas.
Cancers
(Basel). 2025 Dec 4;17(23):3880. doi:
10.3390/cancers17233880. PMID:
41375081. Review. ˍ
2026
Hata N, Otsuji R, Kuga D, Fujioka Y, Sangatsuda Y, Hatae R, Fudaba
H, Momii Y, Mizoguchi M, Fujiki M, Yoshimoto K.
Long-term
outcome of nimustine-based chemotherapy for oligodendroglioma.
Neurooncol
Adv. 2026 Feb 12;8(1):vdag025. doi:
10.1093/noajnl/vdag025. PMID:
41890358. Observational study. ˍ
Katzendobler S, Kuschel L, Zieger N, Thiele F,
Schmutzer-Sondergeld M, Jankovic D, Stürzl R, Harter PN,
Stahl R, Kalasauskas D, Jakola AS, Albert NL, Le Rhun E, Weller M,
Ringel F, Weller J.
Patterns of
radiological response to procarbazine and
CCNU polychemotherapy in patients
with oligodendroglioma.
Neurooncol
Adv. 2026 Aug 6;8(1):vdag184. doi:
10.1093/noajnl/vdag184. PMID:
42603070. ˍ